Company news
Abl Diagnostics Sa (EURONEXT:ABLD) news
Abl Diagnostics Sa news releases on 6ix. Latest, Oct 1, 2026: ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million
Press releases & updates
ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million
October 1, 2026
ABL TEXCELL DIAGNOSTICS RELÈVE SON OBJECTIF DE CHIFFRE D’AFFAIRES 2026 À UNE FOURCHETTE DE 13,5 M€ À 14,0 M€
September 30, 2026
ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report
September 30, 2026
ABL Texcell Diagnostics Reaches a New Strategic Milestone With a Proposed Acquisition of Vela Diagnostics' Activities in Singapore and the United States
September 21, 2026
ABL Diagnostics Becomes ABL Texcell Diagnostics
September 17, 2026
ABL Diagnostics Announces Its Participation in Investor Access @ Maison De La Chimie Paris 2026
September 17, 2026
ABL Diagnostics to Participate in the European Main MidCap Event Paris 2026 on September 30 and October 1, 2026
September 15, 2026
ABL Diagnostics Announces Availability of the Latest All Invest Securities Research Report
September 14, 2026
ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen
September 11, 2026
ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma
September 10, 2026
ABL Diagnostics Confirms Its Change of Scale in the First Half of 2026: Revenue up 90.0%, EBITDA Multiplied by More Than Four and Net Income up 343.3% Compared to the First Half of 2025
September 8, 2026
ABL Diagnostics: Ordinary and Extraordinary General Meeting of September 17, 2026 – Arrangements for the Availability and Consultation of Preparatory Documents
August 27, 2026
ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Number of Shares Constituting the Share Capital
August 27, 2026
ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris
August 7, 2026
ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital
July 27, 2026
ABL Diagnostics Informed that its Reference Shareholder ABL Has Crossed Below the 95% Threshold
July 15, 2026
ABL Diagnostics – Approval of Dividend Distribution for Fiscal Year 2025
July 2, 2026
ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031
June 12, 2026
ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France
June 10, 2026
ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Total Number of Shares Composing the Share Capital
June 9, 2026
ABL Diagnostics: Ordinary and Extraordinary General Meeting of June 30, 2026 – Terms for Making Available or Consulting Preparatory Documents
June 9, 2026
ABL Diagnostics: Sale of a new block of shares by its main shareholder ABL
June 5, 2026
ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026
June 1, 2026
ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025
May 18, 2026
ABL Diagnostics annonce le développement d’un nouveau panel syndromique intégrant la détection du hantavirus par PCR
May 12, 2026
ABL Diagnostics Reports Historic 2025 Annual Results: Net Income Explosion (+246%), Strong Operating Profitability and Global Acceleration
May 11, 2026
ABL Diagnostics: Availability of the 2025 Annual Financial Report
May 7, 2026
ABL Diagnostics Announces Two New Scientific Publications, Reinforcing its Expertise in HIV Sequencing-based Genotyping
April 13, 2026
ABL Diagnostics Expands HIV Sequencing Expertise into TB Drug Resistance Profiling with New NGS Solutions
March 20, 2026
ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL
March 17, 2026
ABL Diagnostics Update Regarding Non-Binding Letter of Intent
February 19, 2026
ABL SA Executes the First Purchase Notice of ABL Diagnostics Shares With Alumni Capital
February 13, 2026
ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger
December 19, 2025
Information on a Temporary Transfer of ABL Diagnostics Shares
December 5, 2025
ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market
November 14, 2025
ABL Diagnostics – Announcement of a Second Agreement Between ABL SA and Alumni Capital
October 22, 2025
ABL Diagnostics: Switch to Continuous Trading on Euronext Paris as From November 3rd, 2025
October 16, 2025